Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Junctucell Biomed Manufacturing GmbH has 1 pending office action currently active in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and is being processed within 1 distinct art unit. This concentration suggests that the company's current innovation is being evaluated within a specific technical niche of the Biotechnology & Pharmaceuticals field, rather than across multiple disciplines.
The busiest examiner, NGUYEN, QUANG, is responsible for the 1 busiest examiner pending action. Since there is 1 distinct examiner involved, the company's current prosecution efforts are focused on the review of NGUYEN, QUANG. The alignment of 1 pending office action with 1 distinct art unit means that the examination will be governed by the specific standards of that single unit.
Practitioners should focus on the specific technical requirements of NGUYEN, QUANG to effectively resolve the 1 pending office action. The presence of 1 distinct examiner and 1 distinct art unit simplifies the management of the portfolio by providing a single point of contact. This focused approach allows for an efficient prosecution process for the 1 busiest examiner pending action currently on the docket.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, QUANG | 1 | 38.0% | +52.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18194383 | GENETICALLY MODIFIED MESENCHYMAL STEM CELLS EXPRESSING ALPHA-1 ANTITRYPSIN (AAT) | NGUYEN, QUANG | 38d overdue |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18194383 | GENETICALLY MODIFIED MESENCHYMAL STEM CELLS EXPRESSING ALPHA-1 ANTITRYPSIN (AAT) | NGUYEN, QUANG | 1631 | §103 | Non-Final OA | 38d overdue | Pending | Mar 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial